Table 1. Patient characteristics.
| Patients (n) | Patients (n) | ||
|---|---|---|---|
| Age (year) | SBR grade | ||
| ⩽55 | 102 | I | 28 |
| >55 | 69 | II | 73 |
| III | 67 | ||
| Not available | 3 | ||
| Postmenopausal | DNA ploidy | ||
| Yes | 92 | Diploid | 58 |
| No | 79 | Aneuploid | 83 |
| Not available | 30 | ||
| Clinical T stage | S-phase fraction | ||
| T1 | 85 | Low | 35 |
| T2 | 73 | Medium | 39 |
| T3 | 6 | High | 52 |
| T4 | 7 | Not available | 45 |
| Histological nodal status | Oestrogen receptors | ||
| N− | 64 | Yes | 111 |
| N+ | 106 | No | 48 |
| Not available | 1 | Not available | 12 |
| Number of positive nodes | Progesterone receptors | ||
| <3 N+ | 66 | Yes | 87 |
| ⩾3 N+ | 39 | No | 68 |
| Not available | 16 | ||
| Capsular invasion | Postoperative radiotherapy | ||
| C I− | 116 | Yes | 162 |
| C I+ | 54 | No | 9 |
| Not available | 1 | ||
| Histologic type | Adjuvant hormonal therapy | ||
| Ductal | 139 | Yes | 117 |
| Lobular | 23 | No | 51 |
| Others | 9 | Not available | 3 |
| Associated extensive in situ carcinomas | Type of chemotherapy | ||
| Yes | 44 | FEC | 147 |
| No | 123 | THEP VCF | 15 |
| Not available | 4 | FNC | 7 |
| EP | 1 | ||
| CMF | 1 | ||
| Intravascular embolus | |||
| Yes | 49 | ||
| No | 107 | ||
| Not available | 15 | ||
FEC=fluorouracil, epirubicin, cyclophosphamide; THEPVCF=theprubicin, vincristine, cyclophosphamide, fluorouracil; CMF=cyclophosphamide, methotrexate, fluorouracil; FNC=fluorouracil, novantron, cyclophosphamide; EP=epirubicin, paclitaxel.